No title
Objectives: Our aim was to compare direct costs for single pill combinations (SPCs) and free-drug combinations for hypertension treatment. Methods: We focused on Australia as a case study and reviewed total costs, and for the patient and government. We reviewed the Australian “Pharmaceutical Benefits Scheme item drug map” considering different thresholds for the government safety net. Total costs
